Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $9.9500 (-2.64%) ($9.8100 - $10.5800) on Wed. Mar. 25, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.67% (three month average) | RSI | 41 | Latest Price | $9.9500(-2.64%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 6.9% a day on average for past five trading days. | Weekly Trend | TGTX declines -12.3% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(59%) IBB(57%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -3.335% in a week (0% probabilities). VIXM(-38%) VXX(-36%) UUP(-10%) TLT(-5%) IGOV(2%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.335% (StdDev 6.67%) | Hourly BBV | 0 () | Intraday Trend | -2.6% | | | |
|
Resistance Level | $10.13 | 5 Day Moving Average | $8.69(14.5%) | 10 Day Moving Average | $8.29(20.02%) | 20 Day Moving Average | $10.13(-1.78%) | To recent high | -37.8% | To recent low | 39.4% | Market Cap | $1.26b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |